01—Abstract
Summary
Summary of the 10-K filed February 19, 2008. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 2007 10-K report highlights a year of significant growth and strategic expansion, driven primarily by strong performance in its Pharmaceutical and Vascular Products segments.
The company achieved a 15.3% increase in net sales, reaching $25.9 billiona, fueled by the continued success of Humira®, strategic acquisitions including Guidant's vascular business and Kos Pharmaceuticals, and favorable international market conditions. Research and Development spending increased substantially to support pipeline development across key therapeutic areas. Despite increased expenses related to acquisitions and R&D, Abbott demonstrated robust operational execution.
The company managed its debt effectively following its strategic acquisitions, maintaining strong credit ratings. Looking ahead, Abbott remains focused on leveraging its product portfolio, advancing its pipeline, and exploring new growth opportunities in both developed and emerging markets. The company's diversified business model across pharmaceuticals, nutritionals, diagnostics, and vascular products provides a solid foundation for sustained growth and value creation for shareholders.
02—Key points
Key Highlights
- Achieved a 15.3% increase in net sales to $25.9 billion in 2007, driven by strong performance across multiple segments.
- Pharmaceutical Products segment sales grew significantly, propelled by the continued success of Humira® and the acquisition of Kos Pharmaceuticals.
- Vascular Products segment experienced substantial sales growth, bolstered by the integration of Guidant's vascular intervention and endovascular solutions businesses.
- Increased Research and Development spending to $2.5 billion, emphasizing investments in key therapeutic areas and pipeline advancement.
- Maintained strong financial health with substantial operating cash flows and managed increased debt levels resulting from acquisitions.
- Continued focus on international market expansion and product launches.
- Demonstrated effective management of regulatory and competitive landscapes, with ongoing efforts to manage patent expirations and generic competition.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2007, Abbott Laboratories kept $0.14.
- Revenue$25.91B100.0%
- Cost of revenue−$11.42B44.1%
- Gross profit$14.49B55.9%
- Operating costs−$9.91B38.3%
- Operating income$4.58B17.7%
- Interest, other & tax−$972.2M3.8%
- Net income$3.61B13.9%
Where FY2007 revenue went
$25.91B- Cost of revenue: $11.42B, 44% of revenue
- SG&A: $7.41B, 29% of revenue
- Net income: $3.61B, 14% of revenue
- Other operating costs: $2.51B, 9.7% of revenue
- Interest, other & tax: $972.2M, 3.8% of revenue
Kept 14% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2007filed February 19, 2008Financial Statements
| Revenue | $25.91B |
| Cost of Revenue | $11.42B |
| Gross Profit | $14.49B |
| SG&A Expenses | $7.41B |
| Operating Expenses | $21.34B |
| Operating Income | $4.58B |
| Interest Expense | $593.14M |
| Net Income | $3.61B |
| EPS (Basic) | $2.34 |
| EPS (Diluted) | $2.31 |
| Shares Outstanding (Basic) | 1.54B |
| Shares Outstanding (Diluted) | 1.56B |
05—Questions
Frequently Asked Questions
What were the key drivers of Abbott's sales growth in 2007?
Abbott's sales growth in 2007 was primarily driven by the strong performance of its Pharmaceutical Products segment, notably the continued success of Humira®, and the strategic acquisitions of Guidant's vascular intervention and endovascular solutions businesses and Kos Pharmaceuticals. Favorable international market conditions also contributed to the overall sales increase.
How did Abbott manage its debt following the significant acquisitions?
Abbott financed its major acquisitions primarily through short-term debt and subsequently issued long-term debt to manage its capital structure. The company maintained strong credit ratings, with AA by Standard & Poor's and A1 by Moody's Investors Service at the end of 2007, indicating effective debt management.
What is Abbott's strategy for research and development?
Abbott significantly increased its R&D spending in 2007 to $2.5 billion. The focus remains on discovering and developing new products and processes, with a majority of expenditures concentrated on pharmaceutical products. Key therapeutic areas include immunology, oncology, neuroscience, pain management, and infectious diseases, with substantial investment in advancing pipeline programs and new indications for existing products like Humira®.
What are the major risks identified by Abbott for its future operations?
Key risks highlighted include the expiration or loss of patent protection leading to increased generic competition, potential intellectual property disputes with competitors, and the impact of cost-containment efforts by governments and private organizations. Additionally, Abbott faces risks related to regulatory compliance, the success of its R&D efforts, manufacturing complexities, and international operational risks.
06—Continue